Instrument Inactif

Communiqués Pediatrx Inc OTC Bulletin Board

Actions

US70532X1072

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board
- ^USD	-

19/02/25	Ignite Proteomics LLC a acquis le code 0249U de Theralink Technologies, Inc. (OTCPK:THER).	CI
07/05/24	IMAC Holdings, Inc. (NasdaqCM:BACK) a acquis les actifs de Theralink Technologies, Inc.	CI

Communiqués

06/03/24	Theralink Technologies : Accelaration/Increase of Financial Obligation - Form 8-K	PU
18/12/23	Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates	AQ
27/06/23	Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer	AQ
04/04/23	Theralink Acquires Exclusive Landmark Immunotherapy Patent including Biomarker from Vanderbilt University	AQ
03/04/23	Theralink® Acquires Exclusive Landmark Immunotherapy Patent including Biomarker from Vanderbilt University	PR
23/02/23	Theralink® Technologies Begins Receiving Payments from Third Party Payors for its Advanced Breast Cancer Assay, Achieving Key Milestone	PR
21/02/23	THERALINK TECHNOLOGIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
01/02/23	THERALINK TECHNOLOGIES, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	AQ
17/01/23	Theralink's Exclusive Licensed RPPA Technology for Commercial Laboratory Testing to Assist the White House Cancer Moonshot Initiative	PR
09/01/23	Theralink® Technologies Appoints Michael Vallone as Senior Director of Commercialization	PR
29/12/22	THERALINK TECHNOLOGIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
09/12/22	THERALINK TECHNOLOGIES, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
01/12/22	THERALINK TECHNOLOGIES, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
01/12/22	Theralink® Technologies Accepted to Present Two Posters at the Upcoming San Antonio Breast Cancer Symposium	PR
29/11/22	Theralink® Technologies Announces Closing of Private Placement and Conversion of Existing Convertible Notes and Convertible Preferred Shares	PR
14/11/22	Theralink® Technologies Receives Final Medicare Reimbursement Rate Determination and PTAN Enrollment	PR
07/11/22	Theralink® Technologies Appoints Dr. Mattia Cremona as its Director of its Biopharma Laboratory	PR
11/10/22	Theralink Technologies to Participate in the LD Micro Main Event Conference on October 25-27	NE
16/09/22	THERALINK TECHNOLOGIES, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	AQ
07/09/22	Theralink® Technologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14	PR
15/08/22	THERALINK TECHNOLOGIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
25/07/22	Theralink® Acquires Two New Milestone Patents Relating to Methods for Treating Breast Cancer	PR
12/07/22	Theralink Technologies : Amendments to Articles of Incorporation/Bylaws/Change in Fiscal Year - Form 8-K/A	PU
12/07/22	THERALINK TECHNOLOGIES, INC. Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K/A)	AQ
07/07/22	THERALINK TECHNOLOGIES, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ